Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $193.56 and traded as low as $190.50. UCB shares last traded at $192.00, with a volume of 2 shares traded.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business’s 50 day moving average is $193.56 and its 200 day moving average is $183.65.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- Buy P&G Now, Before It Sets A New All-Time High
- Will Alibaba’s $53B AI Bet Be the Key to Tech Supremacy?
- Top Stocks Investing in 5G Technology
- Builders FirstSource Is Laying the Foundation for a Rebound
- The 3 Best Fintech Stocks to Buy Now
- Domino’s Pizza Delivers a Buying Opportunity
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
